- Simply Wall St.
Here's Why We're Not Too Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Applied Therapeutics...
- GuruFocus.com
Applied Therapeutics Inc (APLT) Reports Q1 2024 Earnings: A Deep Dive into Financials and ...
Exploring the Financial Landscape and Future Prospects Amidst Regulatory Advances
- GlobeNewswire
Applied Therapeutics Reports First Quarter 2024 Financial Results
Govorestat NDA for Classic Galactosemia under Priority Review, PDUFA target action date of November 28, 2024 Govorestat MAA under review by EMA; Day 120 3-month clock-stop extension granted; decision expected in early Q1 2025Company discussing potential NDA submission under Accelerated Approval for govorestat for treatment of SORD Deficiency with Neurology I Division of FDA NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biop
© 2024 Yahoo. All rights reserved.